BEARINGPOINT
20.6.2022 10:49:12 CEST | Business Wire | Press release
Management and technology consultancy BearingPoint has acquired I Care, a consultancy firm specializing in sustainability strategy development and environmental transition. With the integration, BearingPoint expands its offerings in the area of sustainability consulting and accelerates growth in its key consulting markets.
Established in 2008, I Care has more than 80 employees in France and Brazil and offers consulting services to public organizations, NGOs, private companies and financial institutions to respond to the risks and opportunities of the environmental transition. I Care distinguished itself by developing innovative methods and tools to quantify the performance of actors in the area of low-carbon transition and biodiversity footprint. By hybridizing scientific and strategy consulting skills, I Care has positioned itself as a key player in helping organizations define and implement environmental strategies.
“I Care’s capabilities and service offerings match perfectly with the needs of our clients in Europe. Moreover, we share the same culture of an entrepreneurial, holistic mindset and are trusted advisors for our clients. Together we look forward to becoming the key player in sustainable and environmental transformation consulting in France and entering selected markets internationally,” says Axelle Paquer, Regional Leader for France, Belgium, Luxemburg and Africa at BearingPoint.
BearingPoint , with more than 1,000 employees in France and 4,300 in Europe, has had a dedicated practice in sustainable development since 2010. This includes support for companies and public organizations in strategy, digital responsibility and the calculation of carbon emissions with its emissions calculator solution. BearingPoint is thus strengthening its ability to support clients in all aspects of their sustainable development strategies.
“I Care has a strong reputation for helping clients drive sustainability strategies and environmental transformation. Its proven practice and methodology combined with our transformation and digitalization capabilities will allow us to develop compelling new value propositions for our existing client portfolio in Europe, the US and China,” says Kiumars Hamidian, Managing Partner BearingPoint.
“Joining BearingPoint will enable I Care to accelerate our growth plans within a range of industry sectors in France and open the doors into more markets internationally. We are keen to leverage BearingPoint’s wider capabilities, notably in services such as emissions calculation and digital transformation, to benefit our existing client base. Becoming part of a leading international consulting organization opens up an opportunity to further increase our impact on society. ” says Guillaume Neveux, founder and CEO at I Care.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information about BearingPoint, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
About I Care
I Care is a leading consulting company in the environmental field. Since 2008, I Care assists companies, financial institutions, and public organizations in their transition towards a low environmental impact society.
Combining expertise in strategy, finance, project management, and technical skills, its ambition is to provide clients with global solutions to their environmental challenges with the objective of moving to a sustainable economy. Thanks to its multidisciplinary approach between environmental expertises, consulting, research, the private, and public sectors, I Care has a wide range of skills providing a comprehensive response to the diverse needs in the field of sustainable development.
For more information about I Care, please visit:
Homepage: https://www.i-care-consult.com/
LinkedIn: https://www.linkedin.com/company/i-care-environnement/
Twitter: https://twitter.com/I_Care_Consult
View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005150/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom